The short answer
Petrelintide is a long-acting amylin analogue. Fischer Munch and colleagues published its development in the Journal of Medicinal Chemistry in November 2025 under the description of a potent, stable, long-acting human amylin analogue.
Key facts
- Class
- Long-acting amylin analogue
- Described as
- Potent, stable, long-acting, human
- Development paper
- Fischer Munch 2025 (PMID 41217931)
- Journal
- J Med Chem, 27 November 2025
- Developers
- Zealand Pharma with Boehringer Ingelheim
- Amylin's role
- Satiety signal released after eating
- Authorisation
- None
What amylin does
The paper's own framing describes amylin as a physiological satiety signal released after nutrient intake, which makes it an attractive pharmacological target for weight management. It is co-secreted with insulin from pancreatic beta cells and signals fullness through routes distinct from the incretins.
Why a separate pathway is worth pursuing
Because it is not the incretin pathway. Every compound engaging GLP-1, GIP or glucagon is working within one hormonal system. Amylin signals satiety through different receptors, so it offers a mechanism that could add to incretin effects rather than overlapping with them, which is the rationale behind pairing them in CagriSema.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why the word human in the title matters
Human amylin aggregates into amyloid fibrils, which is what made the native peptide undeliverable as a medicine and why pramlintide substitutes three residues with prolines borrowed from rat amylin. Describing a compound as a stable human amylin analogue is a claim about having solved that problem within the human sequence rather than by importing rodent residues.
Why long-acting is the other engineering achievement
Native amylin has a very short half-life, and pramlintide requires administration with meals. Extending duration to allow infrequent dosing is a separate problem from preventing aggregation, and solving both in one molecule is what a development paper in a medicinal chemistry journal is reporting.
Why the timing is interesting
REDEFINE 4 showed CagriSema, which pairs an amylin analogue with semaglutide, failing to demonstrate non-inferiority against tirzepatide. That result concerns one combination at one dose pair and says nothing about amylin as a target on its own, which a standalone amylin analogue is positioned to address directly.
Regulatory position
Petrelintide holds no marketing authorisation anywhere and is investigational. Nothing supplied on this site is related to it, and no research material is an amylin analogue or an alternative to any licensed medicine.
Frequently asked questions
Why does 'human' amylin analogue matter?
Human amylin aggregates into amyloid fibrils. Pramlintide avoided that by borrowing rat prolines; a stable human analogue solves it within the human sequence.
Why develop amylin on its own?
REDEFINE 4 tested one amylin-plus-GLP-1 combination, not amylin as a target. A standalone analogue addresses that question directly.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedFischer Munch H et al., Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue. J Med Chem 2025 (PMID 41217931)pubmed.ncbi.nlm.nih.gov
- PubMedBailey CJ, Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes. Peptides 2026 (PMID 41747885)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · CagriSema compared to tirzepatide (NCT06131437)clinicaltrials.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- The Amyloid Problem at the Centre of Amylin DesignHuman amylin forms amyloid fibrils. Every amylin medicine is a solution to that, and the two available solutions are instructively different.
- The Class's Defining Safety PropertyGLP-1 amplifies insulin secretion only when glucose is already elevated. Below that threshold the signal does almost nothing - which is the whole point.
- Forcing the Channel Shut Regardless of GlucoseSulfonylureas close the beta cell's potassium channel directly, bypassing the glucose sensing step. That is precisely why they cause hypoglycaemia.
- The Number Depends on Three Things Before the DrugBackground therapy, the glucose threshold used, and how much HbA1c fell all move a hypoglycaemia figure. The compound is often the smallest factor.
- What the Class Reliably ProducesGastrointestinal effects dominate and follow from the mechanism. A 2014 review set out the profile before the current generation existed.